You are here

Article Text

Article menu
Download PDFPDF
Miscellaneous
Lung alert
Cetuximab: a new hope for advanced NSCLC
  1. S Karmali
  1. Correspondence to S Karmali, Medical Student, University College London, London, UK; s.karmali{at}ucl.ac.uk

https://doi.org/10.1136/thx.2009.121012

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Advanced (stage IIIb/IV) non-small cell lung cancers (NSCLCs) are associated with poor survival on current chemotherapy regimes. Epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors are second-line treatment options. This is the first study to investigate a monoclonal antibody against the EGFR cetuximab as a potential first-line treatment option.

    In this multinational open-label study across …

    View Full Text

    Footnotes

    • Provenance and peer review Not commissioned; not externally peer reviewed.